Biotechnology Applications of Peptides¶

Key Summary: Peptides are used across biotechnology as culture surfaces, discovery scaffolds, vaccine antigens, biosensor recognition elements, biomaterials, crop protection agents, and diagnostic reagents. Their sequence is fully defined, which makes their properties reproducible and their behavior at an interface predictable. This review covers seven application areas and separates established results from open research questions. Research use only.

Introduction¶

Peptides occupy the space between small molecules and proteins, and much of applied biotechnology works in exactly that space. A chain of 5–50 residues can carry a binding motif, a signaling sequence, or a self-assembly instruction with the specificity of a protein and the reproducibility of a defined chemical. Because peptides are built from a small alphabet of amino acids, their charge, solubility, and secondary structure can be tuned by design; because they are made by solid-phase peptide synthesis or recombinant expression, they can be produced as characterized, batch-consistent material rather than as biological extract.

That combination — programmable structure, defined composition — is why peptides show up in so many corners of biotechnology research: as surfaces that make culture systems work, as scaffolds in discovery pipelines, as the active ingredient in vaccine design, as recognition elements in sensors, as building blocks for materials, as crop protection agents, and as antigens in diagnostics. This page reviews the research behind each of those applications, separating what the literature has established from what remains unresolved. All content is presented for research and educational purposes only.

Peptides in Cell Culture¶

Culture outcomes depend heavily on the cell–material interface, and that interface is increasingly made of peptides. Animal-derived matrices such as Matrigel support cell growth but come with undefined composition and batch variability; synthetic peptide coatings remove both problems. The clearest demonstration comes from a vitronectin-derived peptide surface (Synthemax), in which a short bioactive peptide is grafted onto a polymer backbone. The surface supported attachment, spreading, and proliferation of human induced pluripotent stem cells, as well as their lineage-specific differentiation, under fully xeno-free conditions (7).

On a smaller scale, the fibronectin-derived Arg-Gly-Asp (RGD) motif is the most widely used cell-adhesion sequence in research. Because most synthetic polymers and hydrogels present no adhesion signals at all, RGD peptides are routinely incorporated into materials so that cells can attach and spread through integrin engagement (15). Self-assembling peptides add a third dimension: RADA16-class sequences form nanofiber hydrogels with water content above 99% that serve as completely synthetic extracellular matrices for 3D cell and tissue culture (8, 9). Where the goal is getting cargo into cells rather than keeping cells attached to a surface, cell-penetrating peptides such as Tat- and penetratin-derived sequences deliver conjugated nucleic acids, proteins, and nanoparticles in vitro (16).

Peptides in Drug Discovery¶

The medical use of peptides is not a recent development — insulin has been in the clinic for a century — but the pipeline around them has broadened decisively. More than 80 peptide drugs have reached the market, covering indications that include diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection, and chronic pain (1). Two of the more unusual arrivals came from venoms: exenatide, a GLP-1 receptor agonist derived from Gila monster venom, and ziconotide, a cone snail peptide that inhibits voltage-gated calcium channels — both identical to the native venom peptides (1).

Discovery now leans as much on libraries as on rational design. Phage display and mRNA display generate macrocyclic and constrained peptides that can engage targets — extracellular receptor sites, protein–protein interfaces — that conventional small molecules reach with difficulty (1, 2). In parallel, medicinal chemistry has chipped away at the classic weaknesses of peptides: proteolytic instability, short half-lives, and poor membrane permeability (2, 3). The net effect is a development landscape in which peptides and deliberately "peptide-like" molecules increasingly fill the therapeutic space between small molecules and antibodies.

Peptide Vaccine Development¶

Peptide vaccines deliver defined epitopes instead of whole pathogens or full-length proteins. The logic is appealing — focus the immune response on the sequences that matter — but the field learned early that minimal short epitopes are poorly immunogenic on their own. The turn toward synthetic long peptides (SLPs) changed the picture: longer sequences must be processed by antigen-presenting cells before presentation, a requirement that produces more coordinated T-cell activation than short peptides achieve (6). A landmark test came in a phase 2 study of women with HPV-16-positive, grade 3 vulvar intraepithelial neoplasia. Vaccination with overlapping long peptides covering the HPV-16 oncoproteins E6 and E7 produced clinical responses in 12 of 20 patients (60%) at three months and 15 of 19 (79%) at twelve months, and all patients showed vaccine-induced T-cell responses (5).

Personalized neoantigen vaccines extend the same principle to mutations identified by tumor sequencing. In an early-phase melanoma study, a vaccine consisting of predicted neoantigen long peptides combined into pools with poly-ICLC produced robust T-cell responses against multiple encoded epitopes (4). What remains unresolved is largely immunological: predicting which epitopes will actually be presented, understanding why response depth varies between patients, and establishing which adjuvants and delivery regimens produce the most durable immunity (4, 6).

Peptide Biosensors¶

A biosensor needs a recognition element that binds its target specifically and survives its working environment. Peptides satisfy the first requirement by design — display selection can find sequences against a specified analyte — and perform well on the second: short linear peptides form dense, ordered self-assembled monolayers on gold surfaces, producing a high concentration of binding sites at the sensing interface (11). Peptide-based designs now span electrochemical, optical, and mass-sensitive platforms, and reviews of the field credit peptide recognition elements with high specificity, sensitivity, and stability (10).

The applications are practical rather than speculative. Food-safety researchers have built peptide-based sensors and electronic noses for foodborne pathogens, where robustness and cost matter as much as detection limits (11). Enzyme-cleavable peptide substrates, long used to measure protease activity, are now standard components of fluorescent and electrochemical sensor designs (10). The open problems cluster around real-world use: signal stability over time, sensor regeneration between measurements, and validation in complex, unprocessed sample matrices (10, 11).

Peptide Biomaterials and Tissue Engineering¶

The nanofiber hydrogels described under cell culture belong to a broader materials story. Ionic self-complementary peptides — a class discovered after a repeating yeast-protein motif (EAK16-II) was synthesized and unexpectedly assembled into ordered structures — and their descendants, including RADA16-I, self-assemble in water into β-sheet nanofibers that entangle into hydrogels (9). Because the assembly is sequence-programmed, properties such as charge pattern, fiber morphology, and stability can be tuned by design rather than by formulation (8, 9).

Functionality follows the same logic used in culture systems: motifs are grafted onto the material. RGD-functionalized scaffolds improve cell adhesion, proliferation, and differentiation in tissue-engineering studies, with the bone and cartilage literature especially well developed (15). Peptide biomaterials are also attractive for what they avoid — defined chemistry instead of extracted animal collagen, controllable epitope display, and degradation products that are ordinary amino acids. The engineering work that remains is substantial: matching the mechanical behavior of native tissue, controlling degradation kinetics, and generating long-term in vivo evidence (9, 15).

Crop Protection and Agricultural Biotechnology¶

Plant disease management relies heavily on chemical pesticides, and resistance concerns plus environmental pressure have pushed researchers toward biological alternatives. Antimicrobial peptides (AMPs) — both plant-derived and synthetic — have become leading candidates: they act on microbial membranes and other essential cellular structures with broad-spectrum activity, and resistance develops less readily than against many single-target conventional agents (12). Application research has moved beyond simple sprays in some cases, with seed coatings and combination formulations alongside other biocontrol agents under investigation (12).

The agbiotech angle extends to the plants themselves: expressing AMP genes in crops to raise disease resistance is an active research strategy (12). Commercial translation, however, remains limited. Field stability — peptides are vulnerable to plant proteases and ultraviolet exposure — production cost, and the regulatory treatment of peptide-based crop protection products are the recurring obstacles identified in the literature (12).

Diagnostics¶

Serological testing depends on antigen quality, and synthetic peptide antigens offer a structural advantage: they present exactly the epitope an assay needs, without culture-derived or recombinant material overwhelming the signal. A systematic review of peptide-based serological tests for leishmaniasis concluded that synthetic peptides are a recommendable approach for diagnosing both the visceral and tegumentary forms of the disease, positioning them as realistic alternatives to crude antigen preparations (13). The veterinary literature tells a similar story across a broad range of pathogens: one review catalogued 23 studies using synthetic peptides to detect 21 different infectious diseases in domestic and non-domestic animals (14).

Beyond serology, peptides appear in diagnostics as assay recognition elements, enzyme substrates, and imaging probes — the same properties that make them useful in biosensors (10). The remaining work is validation-heavy: assay performance must be demonstrated for each pathogen, population, and sample type, and reagent quality (purity, peptide content, counterion control) has to be reproducible for results to transfer between laboratories (13, 14).

What Is Established¶

Peptide drugs are a mature therapeutic class: more than 80 are marketed, and display technologies plus medicinal chemistry continue to widen the pipeline (1, 2, 3).
Synthetic peptide surfaces support defined, xeno-free culture of human induced pluripotent stem cells, including lineage-specific differentiation (7).
RGD-functionalized materials improve cell adhesion and downstream differentiation in tissue-engineering models (15).
Self-assembling peptides form stable nanofiber hydrogels that function as synthetic extracellular matrices in 3D culture (8, 9).
Long-peptide vaccines induce T-cell immunity in humans, with clinical responses documented in HPV-16-driven disease and neoantigen-specific responses in melanoma (4, 5).
Peptide recognition elements perform across electrochemical, optical, and mass-sensitive sensor formats, including foodborne-pathogen detection (10, 11).
Synthetic peptide antigens improve the specificity of serological assays, with systematic-review support in leishmaniasis and broad application in veterinary diagnostics (13, 14).
Antimicrobial peptides show broad-spectrum activity against plant pathogens and are being pursued as biocontrol agents (12).

Research Gaps¶

Delivery and stability: proteolytic degradation, short circulation half-lives, and poor membrane permeability still constrain therapeutic and intracellular applications; chemistry solutions such as stapling and macrocyclization help but are not universal (2, 3).
Vaccine immunogenicity: predicting which epitopes will be presented, ensuring robust responses across patients, and optimizing adjuvants and regimens remain unresolved (4, 6).
Biosensor translation: long-term signal stability, sensor regeneration, and performance in complex, unprocessed samples need further work before large-scale field deployment (10, 11).
Biomaterials: mechanical matching to native tissue, controlled degradation, and long-term host-response data are the recurring gaps for peptide scaffolds (9, 15).
Crop protection: field stability, manufacturing economics, and regulatory pathways for peptide-based products are unresolved (12).
Diagnostics: cross-population validation and standardized reagent quality are prerequisites for broader adoption (13, 14).

The Author's Take¶

Position: In our editorial view, the most durable near-term impact of peptides in biotechnology lies in applications where sequence-defined chemistry directly replaces undefined biological material — surfaces, scaffolds, recognition elements, and antigens — rather than in applications that demand small-molecule-like behavior.

Reasoning: Three observations support this. First, the cases with the clearest published results (xeno-free culture surfaces, hydrogel matrices, peptide serology) all exploit sequence control as the core value proposition rather than as an incidental feature. Second, the perennial peptide weaknesses — proteolysis, permeability — matter least in these settings, which is consistent with progress arriving there fastest. Third, where peptides have struggled as drugs, the fix has been chemical engineering toward "peptide-like" molecules, and that same design discipline transfers directly to sensors, materials, and diagnostic reagents.

Disclosure: This is the editorial opinion of the RPL Peptide Scientific Editorial Team, not a verified experimental finding, and it is not intended as medical or therapeutic guidance.

References¶

Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nature Reviews Drug Discovery. 2021;20(4):309–325. doi:10.1038/s41573-020-00135-8
Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? Journal of Medicinal Chemistry. 2018;61(4):1382–1414. doi:10.1021/acs.jmedchem.7b00318
Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7:48. doi:10.1038/s41392-022-00904-4
Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221. doi:10.1038/nature22991
Kenter GG, Welters MJP, Valentijn ARPM, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New England Journal of Medicine. 2009;361(19):1838–1847. doi:10.1056/NEJMoa0810097
Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nature Reviews Drug Discovery. 2007;6(5):404–414. doi:10.1038/nrd2224
Jin S, Yao H, Weber JL, Melkoumian ZK, Ye K. A synthetic, xeno-free peptide surface for expansion and directed differentiation of human induced pluripotent stem cells. PLoS ONE. 2012;7(11):e50880. doi:10.1371/journal.pone.0050880
Zhang S. Fabrication of novel biomaterials through molecular self-assembly. Nature Biotechnology. 2003;21(10):1171–1178. doi:10.1038/nbt874
Hauser CAE, Zhang S. Designer self-assembling peptide nanofiber biological materials. Chemical Society Reviews. 2010;39(8):2780–2790. doi:10.1039/b921448h
Xiao Y, Zhang T, Zhang H. Recent advances in the peptide-based biosensor designs. Colloids and Surfaces B: Biointerfaces. 2023;231:113559. doi:10.1016/j.colsurfb.2023.113559
Escobar V, Scaramozzino N, Vidic J, et al. Recent advances on peptide-based biosensors and electronic noses for foodborne pathogen detection. Biosensors. 2023;13(2):258. doi:10.3390/bios13020258
Sun D, Jia Z, Zhu J, et al. Antimicrobial peptides and their potential applications in plant protection. Agronomy. 2025;15(5):1113. doi:10.3390/agronomy15051113
Pagniez J, Petitdidier E, Parra-Zuleta O, Pissarra J, Bras-Gonçalves R. A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis. Parasite. 2023;30:10. doi:10.1051/parasite/2023011
Aguilar-Montes de Oca S, Montes-de-Oca-Jiménez R, Vázquez-Chagoyán JC, et al. The use of peptides in veterinary serodiagnosis of infectious diseases: a review. Veterinary Sciences. 2022;9(10):561. doi:10.3390/vetsci9100561
Kumar VB, Tiwari OS, Finkelstein-Zuta G, Rencus-Lazar S, Gazit E. Design of functional RGD peptide-based biomaterials for tissue engineering. Pharmaceutics. 2023;15(2):345. doi:10.3390/pharmaceutics15020345
Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends in Pharmacological Sciences. 2017;38(4):406–424. doi:10.1016/j.tips.2017.01.003

This article is provided for research and educational information purposes only and does not constitute medical or therapeutic guidance. Consult the primary literature for detailed protocols and current best practices.

— Written by the RPL Scientific Editorial Team | Last updated September 2026